Biotivia Resveratrol Research Division Launched

Print |

Resveratrol research arm is open to medical institutions

New York City, N.Y, March 18, 2011 — Biotivia Resversatrol Research Community Services Go On line

Biotivia, a world leading developer and supplier of resveratrol and pterostilbene based health supplements, has launched a resveratrol researcher support division. All aiming at providing top quality trans-resveratrol, pterostilbene and virtually all other advanced botanicals and synthetics to the worlds’ medical and research organisations.

Through facilitating an exchange of knowledge amongst researchers, Biotivia’s objective is to help further the study and research of resveratrol and the ever expanding role it is expected to play in preventing and treating many age related diseases.

More human clinical research and studies are being undertaken using Biotivia resveratrol supplements and resveratrol analogs in their trials than all other other suppliers combined.

Presently several private institutions and public organisations are presently conducting human clinical trials or are recruiting subjects for such research in which Biotivia’s resveratrol supplements or compounds are being used.

The company’s extensive collaboration with global researchers uniquely qualifies Biotivia to assist researchers with knowledge that help them to design studies and develop their study protocols.

Some of the medical and research teams that have published important studies in peer reviewed journals include The Albert Einstein Medical Center, resveratrol’s positive effect on type 2 diabetes. Northumberland, resveratrols effect on coginitive function and found that it increased brain blood flow in subjects by over 200%. Ottawa Hospital, dosage studies and mitochondrial function; and many additional institutions.

Some interesting prospective resveratrol research that Biotivia is involved in includes the effect of resveratrol on Beta Thalassemia at Ferrara University, long term effect on heart patients’ survival rates Stoney Brook Medical College and endocrine functions at Turin University.

Biotivia produces all of its materials and products in pharmaceutical facilities, not supplement mills as do other companies. Furthermore, we go to extremes to protect our advanced compounds from oxidation and deterioration by UV, heat and other environmental factors. Finally, Biotivia uses no additives, expanders, glidants, or other extraneous fillers in any of its products. This means that these substances are removed as possible variables in trials using Biotivia compounds.

James Betz, founder and CEO of Biotivia, said “We are pleased to be able to offer our resveratrol to prestigious research institutions and look forward to becoming the clear choice for such organisations. With our consistent high quality and standards researchers can be assured that they are getting the purest and most potent trans-resveratrol and its derivatives available. Our work with some of the worlds top research facilities is testament to this fact.”

To learn more about resveratrol research and how you can be involved, please visit http://www.biotivia.com/researchers.html

###

About Biotivia LLC

Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and biologically active botanics to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world’s leading developers and suppliers of unique science-based nutritional supplements and award winning skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.

Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi’an, China and Mumbai, India.

Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center, Health Canada, and the University of California. Transmax and Bioforte in particular are being investigated by several major university medical schools as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia most recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers as an alternative to the whole blood transfusions which such patients now require monthly. The Albert Einstein Medical College published a study which elucidated the beneficial effects of Biotivia’s proprietary resveratrol on glucose tolerance and mitochondria function in pre-diabetic subjects. Bioforte was also shown to more than double brain blood flow in a study done at the University of Northumbria in the UK.

Biotivia’s resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both ‘most potent’ and ‘best value’. Transmax has been certified as an investigational drug by the NIH, an endorsement of its safety and purity.

Most of Biotivia’s supplements have been certified Vegan by the American Vegetarian Association.

Important Caveat: Neither PteroMax nor any Biotivia product has been definitively shown to diagnose, prevent or cure any age related diseases. PteroMax is not intended to diagnose, prevent, treat or cure any disease. Studies done in vitro and on animals do not always translate into the same biological effect when taken by human subjects. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art government inspected pharmaceutical facilities in accordance with CGMP and USP standards.